PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21115933-0	2010	Comparative effect of finasteride and dutasteride on chromogranin A levels.	Finasteride	22-33	chromogranin A	Homo sapiens	53-67	
21115933-1	2010	UNLABELLED: The aim of this study was to verify and to compare in benign prostatic hyperplasia (BPH) patients, the effect of finasteride versus dutasteride therapy on chromogranin A (CgA) serum levels, as a marker of neuroendocrine (NE) differentiation.	Finasteride	125-136	chromogranin A	Homo sapiens	167-181	
21115933-1	2010	UNLABELLED: The aim of this study was to verify and to compare in benign prostatic hyperplasia (BPH) patients, the effect of finasteride versus dutasteride therapy on chromogranin A (CgA) serum levels, as a marker of neuroendocrine (NE) differentiation.	Finasteride	125-136	chromogranin A	Homo sapiens	183-186	
21115933-4	2010	RESULTS: In both Group A (finasteride) and Group B (dutasteride), but not in Group C (no therapy), a statistically significant increase (p<0.05) in serum CgA levels was found at the three- and six-month intervals of therapy when compared with the start.	Finasteride	26-37	chromogranin A	Homo sapiens	157-160	
19443407-10	2009	Seemingly, finasteride treatment reduces PC prevalence in pts free of NED but elevates the number of aggressive carcinomas in CgA-positive pts only if continuous treatment is applied.	Finasteride	11-22	chromogranin A	Homo sapiens	126-129